Urinary Antibacterial And Antiseptic Pharmaceuticals Market Segment By Top Manufacturers, Marketing Channel, Global Regions And Forecast Research 2022-2032

Urinary Antibacterial And Antiseptic Pharmaceuticals Market purposes are anticipated to grow at a CAGR of 4.3% over the course of the projected period. The market is predicted to be worth US$ 44.2 billion in 2022 and US$ 67.34 billion by 2032.

Urinary tract infection refers to bacterial infection in any part of urinary system such as urethra, ureters, bladder and kidney. Urinary tract infections are common in patients which are using urinary catheter, diabetics and elderly people having compromised immunity. Most of the urinary infections are caused by E. coli and S. aureus. Urinary tract infections are mostly treated with antibacterial drugs such as ciprofloxacin, azithromycin, penicillin and others.

Urinary antiseptics such as nalidixic acid, nitrofurantoin etc. can also be effectively used for management of urinary tract infections, these are the drugs which are excreted in urine and show their antiseptic action in the bladder. The choice of treatment depends on type of infectious bacteria and patient history, complicated urinary tract infections leads to kidney damage and may need hospitalization. According to National Institute of Diabetes, Digestive and Kidney Diseases (NIH), urinary tract infection is the second most common type of infection and approximately 8.1 Mn patients visit every year to their physician concerning urinary tract infection.

Urinary Antibacterial and Antiseptic Pharmaceuticals Market: Drivers and Restraints
Increasing recurrence rate for urinary tract infections is the major driver for the growth of urinary antibacterial and antiseptic pharmaceuticals market. Other factors influencing growth of urinary antibacterial and antiseptic pharmaceuticals market can be increasing incidence of diabetes, rising cases of catheter-associated urinary tract infections and expanding indications of drugs, availability of combination products, etc. According to Center for Disease Control and Prevention (CDC), 75% of the hospital acquired urinary tract infections are associated with the catheter use. Major restraint for growth of global market for urinary antibacterial and antiseptic pharmaceuticals is increasing bacterial resistance to antibiotics.

Urinary Antibacterial and Antiseptic Pharmaceuticals Market: Segmentation
The global urinary antibacterial and antiseptic pharmaceuticals market is classified on the basis of product type, distribution channel and geography.

Based on product type, the global urinary antibacterial and antiseptic pharmaceuticals market is segmented as follows:
Antibacterial
Antiseptic

Based on distribution channel, the global urinary antibacterial and antiseptic pharmaceuticals market has been segmented as follows:
Hospital pharmacies
Pharmacy & Drugstores
E-commerce

Urinary Antibacterial and Antiseptic Pharmaceuticals Market: Overview
The global urinary antibacterial and antiseptic pharmaceuticals market is expected to witness sluggish growth due to huge competition between generic players in major markets. Antibacterial product segment is anticipated to hold maximum market as it is the first line treatment for urinary tract infections. Hospital end user segment will continue to lead the global market for urinary antibacterial and antiseptic pharmaceuticals market due to increasing usage of urinary catheters among patients. According to CDC data, 15-25% of all hospitalized patients require catheter use during their hospital stay. Several new treatment options such as monoclonal antibodies are being developed for infection which can influence the market.

Urinary Antibacterial and Antiseptic Pharmaceuticals Market: Region-wise Outlook
Geographically, the global urinary antibacterial and antiseptic pharmaceuticals market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Europe is anticipated to lead the global market for urinary antibacterial and antiseptic pharmaceutical due to greater incidence community acquired urinary tract infections, followed by North America. However, the market is expected to register decline in revenue in the regions of North America and Europe. The Asia Pacific market for urinary antibacterial and antiseptic pharmaceuticals is anticipated to exhibit moderate growth.

Urinary Antibacterial and Antiseptic Pharmaceuticals Market: Key Players
Some of the key market players in global urinary and antiseptic pharmaceuticals market are Pfizer Inc., AstraZeneca Plc., Merck & Co., GlaxoSmithKline Plc., Bayer Pharma AG, Johnson & Johnson Private Limited, Daiichi Sankyo Company Limited and others.

0

0